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DISSERTATION ABSTRACT 
 
Devika Pooja Rajen Gates 
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June 2011 
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Approved:__________________________________________ 
     Dr. J. Andrew Berglund           
 
 
Muscleblind-like 1 (MBNL1) is a splicing factor whose improper cellular 
localization is a central component of myotonic dystrophy (DM). In DM, the lack of 
properly localized MBNL1 leads to mis-splicing of many pre-mRNAs.  The mechanism 
by which MBNL1 regulates it pre-mRNA targets is not well understood.  In order to 
determine the mechanism by which MBNL1 regulates alternative splicing, a consensus 
RNA binding motif for Mbl (the Drosophila ortholog of MBNL1) and MBNL1 were 
determined using SELEX (Systematic Evolution of Ligands by Exponential Enrichment).  
These consensus motifs allowed for the identification of high affinity endogenous sites 
within pre-mRNAs that are regulated by MBNL1.  In vitro binding studies showed that 
MBNL1 bound to RNAs that contained the consensus motif surrounded by pyrimidines.   
Some of these sites were identified upstream of exon 5 within the MBNL1 pre-
mRNA, and we have shown that MBNL1 auto-regulates the exclusion of exon 5 in HeLa 
cells. The region of the MBNL1 gene that includes exon 5 and flanking intronic sequence 
is highly conserved in vertebrate genomes.  The 3’ end of intron 4 is non-canonical in 
that it contains an AAG 3’ splice site and a predicted branchpoint that is 141 nucleotides
v 
 from the 3’ splice site.  Using a mini-gene that includes exon 4, intron 4, exon 5, intron 5 
and exon 6 of MBNL1, we show that MBNL1 regulates inclusion of exon 5.  Mapping of 
the intron 4 branchpoint confirms that branching occurs primarily at the predicted distant 
branchpoint. Structure probing and footprinting reveal that the highly conserved region 
between the branchpoint and the 3’ splice site is primarily unstructured, and MBNL1 
binds within this region of the pre-mRNA, which we have termed the MBNL1 response 
element.  Deletion of the response element eliminates MBNL1 splicing regulation and 
leads to complete inclusion of exon 5, which is consistent with the suppressive effect of 
MBNL1 on splicing. 
This dissertation includes previously published co-authored material as well as 
my recent co-authored material that has been submitted for publication.
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CHAPTER I 
INTRODUCTION 
 
Alternative Splicing 
Splicing of pre-mRNAs is an important event that contributes to a diverse 
proteome as well as the regulation of gene expression.  It is estimated that more than 90%  
of human genes undergo alternative splicing [1, 2].  To produce a functional mRNA, 
introns (non-coding regions) must be accurately removed and the exons (coding regions) 
must be carefully ligated together to form a functional protein.   
Each exon within a pre-mRNA can undergo a different type of splicing.  For 
instance, most exons are constitutive which means they are included in the final mRNA.  
Cassette exons are regulated such that they are sometimes included or sometimes 
excluded.  In pre-mRNAs with many cassette exons, you can have mutually exclusive 
splicing where if one exon is excluded, the other exon will be included. Additionally, 
alternative 5’ or 3’ splice sites can be used which alter the size of the exon.  Differences 
in splice site choice or skipping of exons commonly results in different protein isoforms, 
thereby allowing one gene to produce many different proteins.  
The removal of introns and ligation of exons relies heavily on special sequences 
within introns that are recognized by the splicing machinery. Important sequences include 
the 5’ splice site (GURAGU), the branch point sequence (YURAY), the polypyrimidine 
tract (runs of pyrimidines) and the 3’ splice site (YAG).  Different proteins bind to these 
sequences and with the aid of U1, U2, U4, U5 and U6 snRNPs (small nuclear 
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ribonucleoproteins), splicing occurs (Figure 1).  During the splicing process, different 
complexes form on the pre-mRNA to aid in splicing.  In early (E) complex, the U1 
snRNP is bound to the 5’ splice site, U2AF35 is bound to the 3’ splice site, SF1 is bound 
to the branchpoint sequence and U2AF65 is bound to the polypyrimidine (PY) tract.  
When U2 snRNP binds, it replaces SF1 and A complex is formed.  U2AF65 and U2AF35 
leave and the tri snRNP (U4/U5/U6) arrive to form B complex.  In B complex the 
spliceosome undergoes a conformational change to form the C complex where now the 
U6 snRNP is bound to the 5’ splice site (5’ ss) and U1 and U4 snRNP are removed. Once 
C complex has formed, splicing can occur [3]. 
 
 
Figure 1.  Splicing occurs via two transesterification reactions followed by a ligation.  
SF1 and U2AF65 bind the branch point and polypyrimidine tract, respectively. U2AF35 
binds to the 3’ splice site and the U1 snRNA binds the 3’ splice site to make the E 
complex.   In complex A, U2 snRNA takes the place of SF1 and ATP is hydrolyzed.  In B 
complex, U4, U5 and U6 bind the intronic region and the U2 snRNA continues to bind 
the same area.  In C complex the U2/U6 snRNA catalyzes the transesterification 
reactions. Finally the lariat is released and exons are ligated together by ATP hydrolysis. 
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Splicing occurs by two transesterification reactions followed by ligation of the 
coding regions [4].  In the first step, the 2’-hydroxyl group of the branchpoint adenosine 
attacks the phosphate at the 5’ ss, thereby cleaving the 5’ exon and ligating the 5’ end of 
the intron to the branchpoint adenosine 2’-hydroxyl resulting in a lariat structure.  The 
second transesterification step involves attacking the 3’ end of the intron by the 3’-
hydroxyl of the removed exon.  This allows the two exons to ligate together and form the 
mature mRNA.   
While the proteins involved in the spliceosome complex are very important, there 
are other proteins that aid in splicing called alternative splicing factors.  Alternative 
splicing factors aid in the regulation of either inclusion or exclusion of an exon by 
assisting in splice site choice.  Alternative splicing factors can do this using many 
different mechanisms.   Muscleblind-like 1 (MBNL1) is one such splicing factor and in 
this thesis I address how it interacts with RNA and how it regulates the alternative 
splicing of its own pre-mRNA. 
Myotonic Dystrophy and Alternative Splicing 
Myotonic dystrophy (DM) is a dominantly inherited neuromuscular disorder and 
is the most common form of muscular dystrophy in adults. Two genes, and thus two 
genetic loci are associated with myotonic dystrophy, causing two different diseases with 
similar symptoms.  DM patients show peculiar and seemingly un-related symptoms of 
which a few are: insulin resistance, cardiac abnormalities, myotonia and progressive 
muscle weakness.  Myotonic dystrophy type 1 (DM1) is caused by a (CUG)n (where n is 
a number great than 50) expansion in the 3’ untranslated region (UTR) of the dystrophia 
myotonica protein kinase (DMPK) gene [5].  Myotonic dystrophy type 2 (DM2) is caused 
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by a (CCUG)n expansion in the first intron of the Zinc Finger 9 (ZNF9) gene [6].  
Individuals afflicted with DM1 have anywhere from 50 to greater than 4000 CUG repeats 
in the 3’ UTR of the DMPK gene [6].  Larger repeat size correlates with increased 
severity of the disease as well as younger age of onset. 
DM1 is caused by an RNA gain of function, where the CTG expansion is 
transcribed to CUG repeats.  The RNA gain of function hypothesis was first suggested 
when the following was observed;  the loss of function of the DMPK gene or surrounding 
genes didn’t cause DM1 [7, 8], long CTG repeats that are transcribed to CUG accumulate 
in nuclear foci [9] and the observation that the 3’ UTR of the DMPK gene containing 200 
CTG repeats is enough to cause myotonia [10].  Evidence of the RNA gain of function 
model was provided by a mouse model containing 250 CTG repeats in the human skeletal 
a-actin gene.  These mice developed myotonia and muscle histology similar to DM1 [5] 
suggesting that CUG repeats alone can induce DM1 like symptoms. 
 Long CUG repeats sequester a family of RNA binding proteins, the muscleblind-
like (MBNL) proteins [11, 12].  The human proteins (MBNL1, MBNL2 and MBNL3) 
derived their name (muscleblind-like) from the founding member of this family, the 
Drosophila muscleblind gene (Mbl), which was shown to be important for muscle 
terminal differentiation and proper eye development [13, 14].  In 2003 Kanadia and 
colleagues determined that when the mouse MBNL1 gene is disrupted, it results in 
muscle, eye and aberrant splicing that is characteristic of DM.  In 2004 Ho and 
colleagues suggested that MBNL1 was an alternative splicing factor that regulates the 
alternative splicing of the transcripts observed to be mis-spliced in DM and they showed 
that MBNL1 and MBNL2 regulate the splicing of the TNNT2 and IR pre-mRNAs, two 
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genes that are mis-spliced in DM1 [15, 16].  This observation provided more evidence for 
the RNA gain of function model, where the sequestration of MBNL1 to expanded CUG 
repeats causes the aberrant splicing of several MBNL1 regulated pre-mRNAs.  
Regulation of alternative splicing often results in the formation of an adult isoform, 
however, aberrant splicing caused by the sequestration of MBNL1 results in the 
expression of the neonatal isoform [17].  The pre-mRNA transcripts that are mis-spliced 
when MBNL1 is sequestered, correlate with disease symptoms.  For example, the mis-
splicing of the TNNT2, CLCN1 and SERCA pre-mRNAs cause cardiac abnormalities, 
myotonia and the dis-regulation of intracellular skeletal muscle calcium homeostasis.  
The list of mis-spliced transcripts in DM is partially complete with 24 known transcripts 
[18].  
 Another key splicing factor involved in DM is CUG-BP1, which is a conserved 
heterogeneous nuclear ribonucleoprotein (hnRNP) and binds RNA that contains CUG 
repeats [19, 20].  MBNL1 and CUG-BP1 can behave in an antagonistic manner for some 
pre-mRNAs where if MBNL1 regulates the exclusion of an exon, CUG-BP1 regulates 
inclusion of that same exon [6].  CUG-BP1 protein levels are significantly increased in 
DM. It has been shown that the inclusion of TNNT2 exon 5 is also regulated by CUG-
BP1, therefore the sequestration of MBNL1 and over-expression of CUG-BP1 both lead 
to the splicing defect observed in this transcript [15].  More recently it has been shown 
that MBNL1 and CUG-BP1 do not appear to co-regulate very many transcripts [21, 22]. 
The Muscleblind Family of Proteins 
MBNL proteins bind pre-mRNA through conserved CCCH zinc fingers.  Human 
MBNL homologs (MBNL1, MBNL2 and MBNL3) are regulators of alternative splicing 
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and help promote the inclusion or exclusion of specific exons.  MBNL1 and MBNL3 are 
involved in muscle differentiation and MBNL2 is involved in integrin α3 subcellular 
localization [23-25].  Alternative splicing of MBNL1, MBNL2 and MBNL3 genes gives 
rise to nine, three and six protein isoforms [26, 27].  MBNL1 and MBNL2 are expressed 
in the brain, kidney, liver pancreas and muscle cells, however, MBNL1 is more abundant 
in the heart and skeletal muscle while MBNL2 levels are similar in all the tissues listed.  
MBNL3 is expressed at much lower levels in the tissues listed above but is found in high 
levels in the placenta [24, 26]. 
 Drosophila contains one muscleblind gene (Mbl), which shows conservation to 
the human MBNL gene in the zinc fingers.  Where MBNL proteins contain four zinc 
finger domains, Mbl proteins contain two zinc finger domains.  It has been hypothesized  
that a duplication of the first two zinc fingers occurred before the divergence between 
urochordates and vertebrates, giving rise to the more modern MBNL proteins with four 
zinc fingers [11].  Mbl contains four splice isoforms (Mbl A, B, C and D) all of which 
include the two zinc finger domains.  Mbl C is highly expressed throughout the embryo, 
larval and pupal stages, while Mbl B and A are expressed at lower levels.  Mbl D is 
expressed at the end of the larval stage and the beginning of the pupal stage [28].  The 
expression profile of MBNL and Mbl proteins suggests that they are involved in a 
developmental process.  The binding specificity of Mbl and MBNL are discussed in 
chapters II and III and contain previously published co-authored material. 
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MBNL1 Binding and Alternative Splicing of Pre-mRNA Transcripts 
Teplova et al. showed that MBNL1 can bind Watson-Crick face of GC 
dinucleotides through its zinc fingers (Figure 2).  The zinc fingers bind RNA by using 
intermolecular stacking and hydrogen bonding interactions.  Zinc finger 3 specifically 
binds GC dinucleotides while Zinc finger 4 specifically binds GCU trinucleotides.  
Currently, it is hypothesized that MBNL1 binds RNA in a looped manner, where every 
zinc finger binds a GC dinucleotide [29]. 
 
Figure 2. MBNL1 zinc finger 4 bound to single stranded RNA.  A crystal structure 
published by Teplova et al. that shows the protein RNA interface of MBNL1 zinc finger 
4 making intermolecular interactions with G2, C3 and U4. 
 
Grammatikakis et al. found that the regions required for splicing regulation in 
MBNL1 and MBNL3 are separate from the zinc finger RNA binding domains [30].  They 
identified core regulatory regions for activation and repression 80 amino acids 
downstream of the N-terminal zinc-finger pair.   
MBNL1 has been shown to regulate exon exclusion of exon 5 of the TNNT2 and 
exon 7A of the CLCN1 pre-mRNAs.  In both cases MBNL1 directly binds the pre-
mRNA.  To regulate exon 5 exclusion of the TNNT2 pre-mRNA, MBNL1 competes with 
the splicing factor U2AF65 to regulate exon 5 [31].  To regulate exon exclusion of 7A in 
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the CLCN1 pre-mRNA MBNL1 binds the 5’ end of exon 7A (thereby masking an exonic 
splicing enhancer) and the upstream intronic region [27]. 
To determine how MBNL1 identifies and regulates its pre-mRNA targets, a study 
on the RNA binding specificity of Drosophila Mbl and MBNL1 was done.  Chapter II 
discusses the binding specificity of Mbl to SELEX RNAs.  The studies from this chapter 
contains co-authored material by Emily Goers, Rodger Voelker and Devika Gates.  The 
results from the studies discussed in Chapter II indicate that Mbl binds RNAs with 
secondary structure.  
Chapter III discusses the identification of a YGCY consensus motif via a doped 
SELEX that MBNL1 binds with high affinity.  Chapter III contains co-authored material 
by Emily Goers, Jamie Purcell, Rodger Voelker and Devika Gates.  The studies in this 
chapter allowed for the identification of novel endogenous MBNL1 binding sites.   
The studies from Chapter II and Chapter III aided in the identification a 90 
nucleotide MBNL1 response element within the MBNL1 pre-mRNA, which is discussed 
in Chapter IV.  Chapter IV contains co-authored material by Devika Gates and Leslie 
Coonrod and contains results that provide insight into how MBNL1 regulates the 
alternative splicing of its own pre-mRNA. 
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CHAPTER II 
 
RNA BINDING SPECIFICITY OF DROSOPHILA MUSCLEBLIND 
 
The work described in this chapter was published in volume 47 of the journal 
Biochemistry in June 2008.  Emily Goers performed the RNA SELEX experiment with 
Drosophila Mbl and performed the characterization of many of the RNA ligands; Rodger 
Voelker performed bioinformatics analysis; I aided in the characterization of the SELEX 
RNAs and determining their binding affinity to Mbl. Dr. J. Andrew Berglund was the 
principle investigator of this work. 
Introduction 
 The human muscleblind protein, MBNL, plays a big role in DM.  There are two 
types of DM, DM1 and DM2.  DM1 is caused by a CTG expansion in the 3’ UTR region 
of DMPK1 gene [32-34] while DM2 is caused by a CCTG repeat expansion in the first 
intron of ZNF9 gene [35].  These two different expansions in two different genes result in 
a disease with a common mechanism.  When the repeat expansions are transcribed, they 
form a double-stranded stem loop structure.  MBNL proteins are sequestered to these 
structures forming nuclear foci, which results in the aberrant splicing of its pre-mRNA 
targets [23, 26].   
 Drosophila has been used as a model organism for understanding myotonic 
dystrophy (DM).  It has been shown that Drosophila overexpressing 162 CUG repeats 
result in Mbl sequestered into nuclear foci but no abnormal phenotypes are observed [36].  
However, the introduction of 480 interrupted CUG repeats result in not only the nuclear 
foci but causes symptoms typical of DM in the muscle and eye as well as other 
degenerative phenotypes [37].  These phenotypes can be rescued with the overexpression 
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of human MBNL1 indicating that Mbl and MBNL1 are functionally conserved.  The 
Drosophila Mbl protein is an excellent model to understand how the muscleblind proteins 
recognize RNA because Drosophila has only one Mbl gene (which has four protein 
isoforms) and only one zinc finger pair. Here we characterize the RNA binding properties 
of Mbl. 
Results 
 Characterization of SELEX RNAs- SELEX was done by Emily Goers with Mbl 
using a library of 1014 RNAs, which contained a 30 nucleotide randomized region with 
flanking constant regions.  After six rounds of SELEX, 25 unique RNA sequences were 
identified and they were classified into three groups depending on their binding affinity 
to Mbl, their secondary structure and the presence of enriched motifs. 
 The binding affinity of SELEX RNAs 20, 22, 24, 28, 30, 34 and other RNAs to 
Mbl was determined using electrophoretic mobility shift assays (EMSA (Figure 3)).   
 
 
Figure 3.  An example of the electrophoretic mobility shift assay (EMSA) used to 
characterize the SELEX RNAs. In this example, RNA #20 bound Mbl with high affinity 
while RNA #30 didn’t bind Mbl. 
 
Characterization of these and other RNAs allowed us to group the SELEX RNAs. 
Group I RNAs contained the AGUCU consensus motif near the 3’ end of the RNA and 
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Group II RNAs contained the AGUCU consensus motif near the 5’ end of the RNA.  
Both Group I and Group II RNAs bound Mbl with a Kd ≤ 50nM.  Group 3 RNAs did not 
contain the AGUCU consensus motif and bound Mbl poorly with Kd values > 300nM 
(Figure 4).  Interestingly, Group I RNAs had a common secondary structure while Group 
II RNAs had a common secondary structure.  This was the result of the AGUCU 
consensus motif binding a sequence in the 3’ constant region.  This observation suggests 
that the SELEX on Mbl may have been biased and the AGUCU consensus motif may not 
be biologically relevant. 
 
Figure 4. SELEX RNAs classified into three groups.  SELEX RNAs were put into 
separate groups depending on whether they contained a consensus motif (highlighted), 
where the motif was located and the predicted secondary structure.  
 
 
 Binding studies with SELEX RNA #20 show Mbl binds structure RNA- SELEX 
RNA #20 was studied in more detail to identify a minimal Mbl binding site and to 
determine whether structure played a role in Mbl binding of the RNA (Figure 5).  RNA 
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#20 contains two stem-loops separated by a short single stranded linker.  In order to 
determine whether Mbl bound the individual stem loops, gel shift assays were done.  We 
observed, that Mbl did not bind stem-loop 1 and bound stem-loop 2 with a Kd of 290nM, 
suggesting that Mbl requires both stem-loops to bind.  However, if stem-loop 1 was 
shortened, Mbl still bound with a Kd of 0.31nM.  Interestingly, RNAs where the 5’ tail 
and 3’ tail were truncated separately did not bind Mbl indicating the importance of these 
regions for RNA binding.  
 
 
Figure 5.  SELEX RNA # 20 binds Mbl with high affinity. To determine whether Mbl 
binds a particular stem-loop, EMSAs were done with stem-loop 1 and stem-loop 2. 
 
Materials and Methods 
Protein Purification. This Mbl construct was expressed in Escherichia coli 
Rosetta cells and grown in LB medium with 50 µM ZnCl2, 50 µg/mL Amp, 25 µg/mL 
chloramphenicol, and 2% glucose at 37 °C. Cells were induced at an OD600 of 0.5-1.0 
with 0.4 mM IPTG at 30 °C for 3 h. Cells were then pelleted and stored at -80°C. The 
pellet was dissolved in lysis buffer (500 mM NaCl, 25 mM Tris (pH 8.0), 10 mM BME, 
and 5% glycerol), sonicated, and centrifuged at 31000g for 15 min. The supernatant was 
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bound to glutathione-agarose beads for 30 min to 1 h at 4 °C. The protein was eluted with 
10 mM reduced glutathione, diluted to 60 mM NaCl, and run over a Source 30Q anion-
exchange column (Amersham). Protein impurities bound to the column, but Mbl did not; 
therefore, flow-through was collected, concentrated, and dialyzed into protein storage 
buffer [50% glycerol, 25 mM Tris (pH 7.5), 5 mM BME, 0.1% Triton X-100, and 500 
mM NaCl] overnight at 4 °C. The presence of the GST tag does not appear to alter RNA 
binding because removing GST did not alter the RNA binding of Mbl. 
Transcription and Kinase Reactions. RNA oligonucleotides were transcribed with 
T7 RNA polymerase and [α-32P]CTP from linearized plasmids, PCR products, or fully 
complementary cDNA oligos. The transcription reaction mixtures were incubated at 37 
°C for 3 h or at 25 °C overnight. RNAs were kinased using T4 polynucleotide kinase 
(New England Biolabs) and [γ-32P]ATP. Both transcribed and kinased RNAs were gel 
purified with 8% denaturing polyacrylamide gels. 
Gel Mobility Shift Assay. Radiolabeled RNA was heated at 95 °C for 3 min and 
then placed directly on ice for 10 min in binding buffer [20 mM Tris (pH 7.5), 5 mM 
MgCl2, and 100 mM NaCl]. RNA was equilibrated to 25 °C for 5 min. Heparin (final 
concentration of 0.5 mg/mL) and loading dye were added to the RNA. Protein was 
serially diluted into protein storage buffer on ice and aliquoted into 2 µL per binding 
reaction mixture at 25 °C. RNA in binding buffer (8 µL) was added to the aliquoted 
protein and allowed to bind for 15-30 min at 25 °C. The RNA concentration was equal to 
or less than the dissociation constant (Kd) value for each reaction. RNA-protein 
complexes (2 µL per binding reaction mixture) were resolved with a native 
polyacrylamide gel (6% 37.5:1 acrylamide/bisacrylamide mixture and 0.5X TB) run at 4 
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°C for 30 min at ∼150 V. The gels were dried and exposed to a phosphoimager screen 
(Molecular Dynamics) overnight at 25 °C. 
Discussion 
 SELEX allowed for the identification of RNAs that bound Mbl with high affinity, 
and the consensus motif AGUCU.  It is clear from the characterization of several SELEX 
RNAs that the AGUCU motif binds the constant region and aids in the creation of 
secondary structure for each RNA.  Characterization of the SELEX RNAs using gel shift 
assays revealed that the RNAs bind in the picomolar to nanomolar range. 
 Further characterization of SELEX RNA #20 showed that it contained two stem-
loops and that both stem-loops are important for Mbl binding.  The 5’ and 3’ tails of the 
RNA were also shown to be important for binding although it is unclear what role the 
tails have in binding.  It is possible that they could be involved in tertiary interactions 
with other regions of the RNA. 
The AGUCU motif that was enriched in Group I and Group II RNAs did not seem 
to be a result of Mbl binding but due to the fact that this motif bound the constant region. 
However, we were able to show that Mbl binds structured RNA with high affinity.  A 
SELEX on MBNL1 will likely yield a different consensus motif. 
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CHAPTER III 
MBNL1 BINDS RNAS THAT CONTAIN A HIGH PERCENTAGE OF 
PYRIMIDINES AND YGCY MOTIFS 
This work was published in volume 38 of the journal Nucleic Acids Research in 
January 2010.  Emily Goers initially identified and performed preliminary expression 
analysis; Jamie Purcell performed the splicing assays; Rodger Voelker performed 
bioinformatics analysis; I aided in the characterization of the SELEX RNAs and potential 
endogenous MBNL1 binding sites. Dr. J. Andrew Berglund was the principle investigator 
of this work. 
Introduction 
Myotonic dystrophy (DM) is a dominantly inherited disorder and is the most 
common form of muscular dystrophy in adults. Two genes, and thus two genetic loci are 
associated with myotonic dystrophy, causing two different diseases with similar 
symptoms.  DM patients show peculiar and seemingly non-related symptoms of which a 
few are: insulin resistance, cardiac abnormalities, myotonia and progressive muscle 
weakness.  Myotonic dystrophy type 1 (DM1) is caused by a (CTG)n (where n is a 
number great than 50) expansion in the 3’ UTR of the DMPK gene.  Myotonic dystrophy 
type 2 (DM2) is caused by a (CCTG)n expansion in the first intron of the ZNF9 gene.  
Individuals afflicted with DM1 have anywhere from 50 to greater than 4000 CUG repeats 
in the 3’ UTR of the DMPK gene [6].  The toxic CUG and CCUG expansions causes a 
gain of function disease on the RNA level by forming stable stem loops that sequester 
RNA binding proteins.  The sequestration of these proteins (not the retention of the 
mutant transcript alone) is thought to cause the diverse symptoms of DM1 and DM2. 
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MBNL1 is an RNA binding protein sequestered by these toxic CUG and CCUG 
repeats and has been shown to regulate the splicing of several different transcripts, 
including the TNNT2 gene and the INSR gene [38].  Symptoms such as insulin resistance 
and cardiac abnormalities have been attributed to the mis-splicing of the insulin receptor 
transcript and the cardiac troponin T transcript respectively, however, the cause of many 
other symptoms have yet to be defined.   
24 different transcripts have been shown to be mis-spliced in myotonic dystrophy 
and of these pre-mRNA transcripts our lab has characterized MBNL1’s TNNT2 binding 
site in detail.  Ho et al. demonstrated that MBNL1 regulates the alternative splicing of the 
TNNT2 pre-mRNA as well as showing that MBNL1 directly binds upstream of the 
regulated exon.  It was next established that the MBNL1 binding site within the TNNT2 
pre-mRNA forms a 32 nucleotide stem loop, which MBNL1 binds to with high affinity 
[39].  
 Emily Goers did a doped SELEX (Systematic Evolution of Ligands by 
Exponential Enrichment) using the 32 nucleotide TNNT2 binding site characterized by 
Warf et al. [39]. The RNA templates contained constant regions that flanked a 
randomized region.  The randomized region consisted of the wild type TNNT2 template 
and was generated such that 51% of the time the wild type nucleotide was used and was 
changed to either of the other three nucleotides 16% of the time.  The doped SELEX 
allowed MBNL1 to sample other residues while having a bias for the endogenous 
TNNT2 binding site.  The RNA sequences that resulted from the five rounds of SELEX 
bound MBNL1 with similar affinity as the 32 nucleotide TNNT2 site.  The fifth round of 
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SELEX produced RNAs that had a higher percentage of pyrimidines and contained 
YGCY motifs. 
Results 
Determining whether the constant regions pay a role in MBNL1 binding-  EMSAs 
were done to determine whether the constant regions of the SELEX RNAs were playing a 
role in the binding of MBNL1.  Gel shifts of RNAs with and without constant regions 
were done and the Kds were compared.  One of the RNAs that was characterized in such 
a manner was the F06 RNA (Figure 6).  The 32mer F06 RNA (which did not contain the 
flanking constant regions) bound similarly to the 81mer F06 RNA (which contained the 
flanking constant regions).  In general, this type of analysis on F06 and several other 
RNAs showed that although the flanking constant regions could slightly influence 
MBNL1’s binding, the randomized 32 nucleotide region contained the primary elements 
required for MBNL1 binding. 
 
 
Figure 6. SELEX RNA F06 with and without constant regions.  EMSAs showed that 
MBNL1 bound F06 RNA with constant regions similarly to F06 without constant 
regions.  In general, MBNL1 bound RNAs without constant regions with slight less 
affinity that RNAs with the constant regions. 
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MBNL1 binds a consensus motif within the 32 nucleotide TNNT2 binding site-  Our lab 
has characterized in detail MBNL1’s 32 nucleotide binding site within the TNNT2 pre-
mRNA.  The doped SELEX took advantage of this binding site and allowed for the 
identification of nucleotides within the TNNT2 binding site that were important for 
MBNL1 binding. 
 RNAs generated for the SELEX were bound to MBNL1, which was bound to 
GST beads. Unbound RNAs were washed away and RNAs that bound were eluted and 
were reverse transcribed (RT) and amplified.  The RNAs underwent this cycle five times, 
at which point EMSAs were done to determine whether MBNL1 bound the SELEX 
RNAs from round 5 with high affinity (Table 1). Round 5 SELEX sequences were 
sequenced and a common YGCY motif was identified.  The sequences were organized 
into two classes, Class I, which had one or more YGCY motifs and Class II, which has 
zero to one YGCY motifs (Figure 7).  Interestingly, MBNL1 bound Class I RNAs with 
higher affinity than Class II RNAs. 
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sequence Kd (nM) 81mer   Kd (nM) 32mer  
WT TNNT2 SELEX  30. ± 20. 20. ± 10. 
D01 25 ± 6   
E01 5 ± 2   
H05 25 ± 15   
C12 a >1.2 µM   
B08 > 1.2 µM  
H06 4 ± 4   
E12 13 ± 9    
B07  15  ± 8 0.7 ± 0.5 
A04  6 ± 5  180 ± 130 
F06 1.0 ± 0.1  9 ± 7 
F06 UCCA ~ 140   
a gray shading refers to SELEX RNA oligomers in 
Class II,  no shading refers to Class I  b CA refers to 
GC to CA mutations in the 5ʼ-YGCY-3ʼ of the 
SELEX RNA. 
 
Table 1.  Binding affinities for selected SELEX sequences:  EMSAs were done to 
determine MBNL1’s binding affinity to SELEX RNAs. 
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Figure 7. Classification of SELEX RNAs.  SELEX RNAs were put into two different 
classes. Class I contained RNAs that contained two or more YGCY motifs and bound 
MBNL1 with high affinity. Class II contained RNAs that contained zero to one YGCY 
motifs and bound MBNL1 with lower affinity. 
 
Mutational analysis of SELEX RNAs reveals YGCY motifs are required for MBNL1 
binding-  To determine whether MBNL1 recognizes the SELEX RNA sequences through 
its YGCY motifs, the F06 RNA was mutated.  The F06 RNA contains 3 YGCY motifs.  
Mutation of the first YGCY (CGCU) motif to UCCA significantly reduces MBNL1’s 
ability to bind the F06 RNA by 140 fold (Figure 8).  
 
 
Figure 8. Mutational analysis of the F06 RNA.  Mutations in the 1st YGCY motif result 
in decreased affinity to MBNL1. 
 
Motif identified in the doped SELEX binds MBNL1 in the context of MBNL1’s 
pre-mRNA targets-The YGCY motif was used to determine potential MBNL1 binding 
sites within the pre-mRNAs that are mis-spliced in myotonic dystrophy.  We searched 
200 nucleotides upstream, downstream and even within the regulated exon of the pre-
mRNA for YGCY motifs in the 24 pre-mRNA transcripts shown to be mis-spliced in 
myotonic dystrophy.  We choose five pre-mRNA transcripts out of the 24 to study in 
more detail.  40-45 nucleotide regions of the MBNL1, MBNL2, SERCA1, GRIN1 and 
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INSR pre-mRNAs that contained YGCY motifs were studied (Figure 9A and 9B).  Two 
potential binding sites within the MBNL1 pre-mRNA called MBNL1 Site #1 and MBNL1 
Site #2 bound MBNL1 with a Kd of 11 nM and 45 nM respectively.  A potential MBNL1 
binding site within the MBNL2 and SERCA1 pre-mRNAs each bound MBNL1 with a Kd 
of 5.8 nM and 15 nM respectively.  The RNAs within the GRIN1 and INSR pre-mRNAs 
that contained YGCY motifs bound with lower affinity.  Comparison of the RNA 
sequences of the potential endogenous MBNL1 binding sites showed that the four RNAs 
that bound MBNL1 with high affinity not only had one or more YGCY motifs but also 
contained a high percentage of pyrimidines, which the GRIN1 and INSR RNAs lacked.   
 
 
Figure 9.  MBNL1 binds 40-45 nucleotide potential endogenous sites.  MBNL1 bound 
potential endogenous sites with YGCY motifs flanked by a high percentage of 
pyrimidines better than RNAs that did not contain a high percentage of pyrimidines. 
 
Mutational analysis of MBNL1 Site #1-  Closer analysis of the five pre-mRNAs we chose 
to study showed that the MBNL1 pre-mRNA had an unusually high amount of 
conservation upstream of the regulated exon (exon 5) as well as within the regulated exon 
itself.  This peaked our interest of this pre-mRNA and we chose to do mutational analysis 
of MBNL1 Site #1.  The predicted secondary structure of MBNL1 Site #1 suggests that 
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this RNA forms a stable stem loop (Figure 10A).  Previous work on MBNL1 has shown 
that this protein likes to bind to GC dinucleotides in RNAs [29].  We therefore decided to 
mutate the GCs within the YGCY motifs to CAs as well as add a UUCG cap, which 
guarantees the RNA will form a stable stem loop so as to not change the secondary 
structure.  This mutant was referred to as MBNL1 CA_CAP (Figure 10B).  When EMSA 
studies were done with MBNL1 CA_CAP we saw abolished binding.   
 
 
Figure 10.  Mutational analysis on MBNL1 Site #1. (A) shows the predicted secondary 
structure of MBNL1 Site #1 and the Kd at which MBNL1 binds this RNA.  Figure (B) 
shows the mutations that obliterated the UGCU motifs and forced a stem loop structure, 
this RNA was called MBNL1 Site #1 CA_CAP.  MBNL1 did not bind MBNL1 Site #1 
CA_CAP. 
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To determine what the effects of this mutation (on only one of the potential 
MBNL1 binding sites) within the MBNL1 pre-mRNA are in vivo, we made these 
mutations in a MBNL1 minigene that was transfected into HeLa cells.  MBNL1 regulates 
exon exclusion of exon 5 within the MBNL1 pre-mRNA.  Transfection of the wild type 
MBNL1 minigene resulted in 70% inclusion of exon 5.  Transfection of the wild type 
MBNL1 minigene with the overexpression of MBNL1 resulted in 8% exon inclusion, 
meaning MBNL1 nearly completely blocks the use of the 3’ splice site adjacent to exon 
5.  Transfection of the mutant minigene resulted in ~90% exon inclusion meaning the 
mutations enhanced the use of this 3’splice site. Transfection of the mutant minigene with 
overexpression of MBNL1 resulted in only ~10% exon inclusion, which means MBNL1 
is still strongly regulating this exon.  These results indicate that MBNL1 either does not 
regulate the exon through this site or that this site is only one of many MBNL1 sites.  It is 
possible MBNL1 site #2 and site #1 work together to regulate splicing.  Additional sites 
may also exist.   
Materials and Methods 
Protein purification. The MBNL1 protein construct, which includes amino acids 
1–260 and contains an N-terminal GST tag, was expressed and purified as previously 
described [39], except for the following differences.  For the lysis of bacterial cells, 
10µg/mL of DNase was added with the lysozyme (1 mg/mL) and the cell extract was 
centrifuged for 30 minutes at 15,000 rpm.  Supernatant was loaded onto GST beads and 
washed with PBS-T buffer (1X PBS and 1%Triton X-100) and eluted with elution buffer 
(10 mM reduced glutathione, 50 mM Tris pH 9.5).   
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Labeling of RNAs for gel mobility shift assay- The RNA was transcribed from 
purified PCR product using T7 RNA polymerase and [α-P32] CTP. 
Gel mobility shift assay was performed as previously described [40] except for 
the following changes. Reactions were run on a 5% polyacrylamide gel (.5X TBE, 5% 
37.5:1 acrylamide:bisacrylamide and 4% glycerol).  The gels were run for 2 hours at 4ºC 
at 170V. 
In vivo splicing. Splicing assays were done as previously described [41], except 
for the following changes.  All reporters were reverse transcribed using a pcDNA3 
plasmid specific antisense primer 5’–AGCATTTAGGTGACACTATAGAAT AGGG–
3’.  The –RT reactions were treated the same as the +RT reactions except that no 
SuperScriptIII was added to the –RT reactions.  The cDNA from the RT reaction (2µL) 
was subjected to 26 rounds of PCR (within linear range) in a 20µL reaction.  PCR 
amplification for all splice products was done using the sense primer 5’–CCACAGGATC 
CGCTTCTTCTTCTTCATGTTGACTAAACCTCAT –3’ and the antisense primer 5’–A 
TTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCA CCCC–3’. 
Discussion 
 Most of the SELEX RNAs have in common multiple YGCY motifs.  Also, 
several of the potential endogenous MBNL1 sites contain multiple YGCY motifs flanked 
by a high percentage of pyrimidines. Much evidence points to MBNL1 requiring high 
pyrimidine content flanking the YGCY motif(s) since the SELEX RNAs have an overall 
bias for uridines, the native TNNT2 site contains a high percentage of uridines and CUG 
and CCUG repeat RNAs are pyrimidine rich.  This suggests that high-affinity MBNL1 
sites require multiple YGCY motifs in pyrimidine rich RNAs. 
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 Of the potential MBNL1 endogenous sites that were tested via EMSA, we used 
Sfold to determine the predicted structure of the RNAs.  The secondary structures of 
these 40-45 nucleotide RNAs ranged from strong stem-loops to much weaker stem-loops. 
There seemed to be no correlation between MBNL1’s binding affinity and RNA 
structure. 
 The doped SELEX provided us with a YGCY consensus motif as well as a set of 
criteria to look for potential endogenous MBNL1 binding sites.  Further examination of 
the 5 potential endogenous targets showed that MBNL1 binds RNA that contains YGCY 
motifs surrounded by pyrimidines.  Mutational analysis of MBNL1 site #1 showed that 
although MBNL1 is no longer able to bind to this RNA in vitro, In vivo the 
overexpression of MBNL1 still causes exon 5 exclusion.  This suggests that MBNL1 may 
work through several sites within the MBNL1 pre-mRNA to regulate exon 5 exclusion.  It 
will be important to determine whether MBNL1 binds and regulates the potential binding 
sites described above.   
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CHAPTER IV 
 
AUTO-REGULATION OF MBNL1 PRE-MRNA 
 
I was the primary contributor to the experiments described below and did all of 
the writing.  Leslie Coonrod was helpful in running the splicing gels.  J. Andrew Berglund 
was the principal investigator for this work. 
Introduction 
Splicing of pre-mRNAs is an important event that contributes to a diverse 
proteome as well as the regulation of gene expression.  It is estimated that more than 90% 
of human genes undergo alternative splicing [1, 2].  To produce a functional mRNA, non-
coding regions must be accurately removed and the coding regions must be ligated 
together.  Splicing occurs by two transesterification reactions that result in removal of the 
intron and ligation of the exons.  This splicing mechanism relies heavily on pre-mRNA 
sequences, proteins and small nuclear RNAs (snRNA) to aid in the different reactions.  
Cis-sequences that are important for splicing include the 5’ splice site (5’ ss), the 
branchpoint sequence, the polypyrimidine (PY) tract and the 3’ splice site (3’ ss).  These 
canonical intronic motifs plus additional regulatory splicing motifs found in exons and 
introns are recognized by splicing factors and snRNPs (U1, U2, U4, U5 and U6) to form 
the spliceosome, which catalyzes intron removal [42].  
There are many splicing factors that are only involved in a sub-set of splicing 
decisions.  These include the human muscleblind-like (MBNL1/2/3) family of RNA 
binding proteins.  The founding member of this family, muscleblind (Mbl), was 
discovered in Drosophila and was shown to be important for photoreceptor 
differentiation and terminal differentiation of muscles [13, 14].  Subsequently, MBNL 
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proteins were found to associate with expanded CUG repeats (located in 3’ untranslated 
region of the DMPK gene) that have been shown to act as a toxic RNA and are at least 
partially responsible for causing myotonic dystrophy type I (DM1) [5].  The expanded 
CUG repeats sequester MBNL proteins into nuclear foci leading to loss of active protein 
[11, 12].  Expanded CCUG repeats within the first intron of ZNF9 also sequester MBNL 
proteins, which is thought to be at least partially responsible for causing DM type 2 
(DM2) [6].  The sequestration of MBNL1 leads to mis-splicing of developmental 
regulated events, and a few of these events have been linked directly to symptoms in 
DM1 and DM2, such as the mis-splicing of the chloride channel (CLN1) leading to 
myotonia [43].  Increased levels of CUGBP1 have also been shown to result in mis-
splicing of certain pre-mRNA transcripts and are linked to causing heart defects found in 
DM patients [6]. 
Exon 5 of both MBNL1 and MBNL2 pre-mRNAs are mis-spliced in DM [18]. 
These paralogous exons are embedded within highly conserved regions of the genome 
[44, 45].  Figure 11A shows the UCSC genome browser view of the conservation 
upstream, downstream and within exon 5 of MBNL1 [The ultra-conserved element 
described by Bejerano and colleagues [44] is underlined in Figure 11B].  This conserved 
exon in MBNL1 and MBNL2 encodes 18 amino acids that are C-terminal of the fourth 
and final Zinc (Zn) finger RNA binding domain. The inclusion of exon 5 causes MBNL1 
and MBNL2 to be localized primarily in the nucleus while isoforms of MBNL1 and 
MBNL2 lacking these amino acids are found both in the nucleus and cytoplasm [27, 46].  
MBNL3 differs from MBNL1 and MBNL2 in that it lacks the conserved region upstream 
of exon 5 as well as the 18 amino acids encoded by exon 5. 
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Figure 11. MBNL1 auto-regulated splicing.  (A) The MBNL1 pre-mRNA contains a 
conserved intronic element upstream of exon 5 (edited from UCSC genome browser).   
The conserved element is predicted by Evofold [47] to contain several secondary 
structures (represented by green boxes).  (B) Schematic of the wild type MBNL1 
minigene containing exon 4, intron 4, exon 5, intron 5 and exon 6.  (C) Exon 5 exclusion 
of the wild type minigene is MBNL1 dependent.  (D) Sequence alignment between 
MBNL1 and MBNL2 that includes the 3’ end of intron 4, exon 5 and the highly conserved 
region of intron 5.  Intronic sequence is in lowercase and exon 5 is capitalized.  The 
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MBNL1 pre-mRNA distant branchpoint is shown in red, the PY tract is shown in blue and 
YGCY (MBNL1 binding sites) motifs are highlighted in black  The sequence underlined 
is the ultra-conserved element described by Bejerano and colleagues.  Intron 4 contains a 
non-canonical AAG 3’ ss and intron 5 contains a weak GTACTA 5’ ss. 
 
We recently identified YGCY as a minimal MBNL1 RNA binding site [40], and 
demonstrated that insertion of multiple copies of this motif into an intron adjacent to an 
exon that is not normally regulated by MBNL1 is sufficient for regulation by MBNL1.  In 
general, the location of the YGCY motifs correlates with the effect (e.g. enhancement or 
suppression) that MBNL1 has on splicing.  When YGCY motifs are located upstream of 
the exon, MBNL1 binding generally leads to exon exclusion; when YGCY motifs are 
located downstream of an exon, MBNL1 binding generally leads to exon inclusion [21, 
40]. Twelve YGCY motifs occur within the first 200 nucleotides of the upstream acceptor 
sequence in MBNL1 but none are found in exon 5 or the donor region (Figure 11B).  The 
intronic sequence upstream of exon 5 in MBNL2 contains 9 YGCY motifs, while exon 5 
and the intronic region downstream (1st 200 nucleotides) only contain one YGCY motif.  
The location of these YGCY motifs is consistent with MBNL1 proteins acting as 
repressors of exon 5 in MBNL1 and MBNL2. Interestingly, the location of most of the 
YGCY motifs upstream of exon 5 in MBNL1 and MBNL2 are conserved (Figure 11B).  
The presence of redundant MBNL1 binding sites (YGCY motifs) in the response element 
(located between the branchpoint and 3’ ss in intron 4) may serve as a way to increase 
binding at lower cellular concentrations of MBNL1. 
Previously, we showed that one mechanism through which MBNL1 acted as a 
repressor was to compete with the basal splicing factor, U2AF65 for binding at the 3’ end 
of the intron [31].  In this example, the MBNL1 binding site overlaps with the PY tract 
(U2AF65 binding site) in intron 4 of the TNNT2 pre-mRNA.  We showed that when 
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MBNL1 bound intron 4 it suppressed U2AF65 binding, resulting in suppression of U2 
snRNP binding.  
The proposed MBNL1 binding sites within intron 4 for the MBNL1 pre-mRNA do 
not appear to overlap with any of the canonical intronic splicing signals.  In addition, the 
architecture of these introns is unique compared to most mammalian introns.  For 
instance, intron 4 of MBNL1 and intron 4 of MBNL2 both have an AAG 3’ ss instead of 
the consensus YAG 3’ ss.  Intron 4 of MBNL1 contains a predicted distant branchpoint 
sequence (TGAT, in red text in Figure 11B) that is 141 nucleotides from the 3’ ss.  For 
MBNL2 the predicted distant branchpoint is also 141 nucleotides away from the 3’ss. 
Interestingly, the sequence conservation of intron 4 between MBNL1 and MBNL2 does 
not extend to the upstream PY tracts and distant branchpoint sequences. The PY tract 
found adjacent to the predicted branchpoint sequence within intron 4 of MBNL1 is a 
canonical or “strong” site for U2AF65 [41], while the PY tract and branchpoint sequence 
for intron 4 of MBNL2 is weaker compared to MBNL1 (Figure 11B).  Introns with distant 
branchpoint sequences typically lack AG dinucleotides between the branchpoint 
sequence and 3’ ss and this region has been termed an AG Exclusion zone (AGEZ).  
Introduction of an AG in this zone can lead to its use as a cryptic 3’ ss.  Introns 
containing long AGEZs (100 nucleotides or greater) are associated with higher rates of 
alternative splicing suggesting that these regions contain regulatory elements [48].  
Interestingly, many exons with AGEZs of 150 nucleotides or longer are within genes that 
are either known to be associated with disease or are of biomedical interest [48].  The 
MBNL1 binding sites are found in the 173 nucleotide AGEZ of intron 4 of MBNL1 and 
in the 141 nucleotide AGEZ of intron 4 of MBNL2.   
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To study the auto-regulated MBNL1 splicing we have created a mini-gene that 
contains exons 4, 5, and 6 of MBNL1 and its intervening introns (Figure 9C).  We show 
that MBNL1 can regulate a non-canonical intron by binding a mostly unstructured 90 
nucleotide response element within the AGEZ, upstream of exon 5.  Smaller deletions 
within the MBNL1 response element did not eliminate MBNL1’s ability to regulate exon 
5 exclusion.  We observed that exon 5 of MBNL1 is primarily regulated through the usage 
of a distant branchpoint and deletion of this branchpoint causes exon 5 skipping.  These 
results combined with previous results suggest that MBNL1 does not negatively regulate 
its target pre-mRNA transcripts through a conserved mechanism. 
Results 
A mini-gene recapitulates auto-regulation of MBNL1 exon 5- The mini-gene 
constructed to study splicing of exon 5 contains the full-length sequences of exon 4, 
intron 4, exon 5, intron 5 and exon 6 (Figure 11C).  The mini-gene was transfected into 
HeLa cells to determine if MBNL1 could regulate splicing of exon 5 in this context.  As 
shown in Figure 11D, when a plasmid that expresses 960 CUG repeats [38] is also 
transfected into the cells, the inclusion of exon 5 increases to 100% compared to 70% 
(Figure 11D).  This change is presumably the result of the CUG repeats sequestering the 
endogenous MBNL proteins.  The inclusion of exon 5 can be nearly completely blocked 
(8% inclusion, Figure 11D) by the over-expression of MBNL1 from a co-transfected 
plasmid.  These results show that protein levels of MBNL1 play a significant role in the 
regulation of  MBNL1 exon 5 and that we can recapitulate MBNL1 regulated splicing in 
this in vivo system. 
Characterization of the highly conserved 3’ end of MBNL1 intron 4- To determine 
if the putative distant branchpoint sequence discussed in the introduction was important 
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for the splicing of intron 4, the sequence ATGAT (proposed branchsite adenosine is 
underlined) was deleted (Figure 12A, referred to as Δbp).  As shown in Figure 12B, the 
deletion of this motif reduced exon 5 inclusion to 10%.  Deletion of the putative 
branchpoint sequence causes the splicing machinery to skip this 3’ ss and select the 
branchpoint and 3’ ss of intron 5 resulting in skipping of exon 5.  These results show that 
this putative branchpoint sequence is necessary for high levels of exon 5 inclusion, 
presumably because it contains the branchsite adenosine.  
In order to directly determine if the adenosine at position –141 within intron 4 
functioned as the branchpoint for this intron, branchpoint mapping was performed.  The 
strategy to capture intron 4 lariats is shown in Figure 12C, and previous published 
protocols were followed [49].  Nested PCR was used to decrease background.  Primers C 
and D were used for the first PCR reaction and primers A and B were used for the second 
reaction (Figure 12C).  From 45 sequences, twenty one mapped to the distant TGAT 
branchpoint (–141 nts), five mapped to the end of what we have portrayed as the PY tract 
(–115 nts), one mapped to a region between the PY tract and 3’ ss (–34 nts) and one 
mapped to the first nucleotide of exon 5 (0 nts), as shown in Figure 12C.  Dots above and 
below the nucleotides in Figure 10D are color coded to correlate with the adenosine that 
may be used as the branchpoint adenosine for each lariat that was sequenced.  The 
remaining 17 sequences either contained multiple templates, sequences that suggested no 
lariat formation, or sequences that did not map to intron 4.  These results are consistent 
with the 5 nucleotide deletion (Figure 12B) and indicate that the distant branchpoint is the 
primary branchpoint for intron 4.   
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Figure 12. Determination of the branchpoint of the 4th intron in the MBNL1 pre-mRNA. 
(A) Schematic of the MBNL1 pre-mRNA showing the predicted MBNL1 binding sites 
(black hatch marks indicate instances of YGCY motifs) and the x represents the deletion 
of the predicted branchpoint (ATGAT) in intron 4.  The mini-gene containing the 
deletion of the predicted branchpoint was termed the Δbp mini-gene. (B) Splicing of the 
wild type and Δbp mini-gene splicing reporters. (C) RT-PCR of intron 4 lariats of the 
MBNL1 pre-mRNA indicates that the 5 nucleotides deleted in the Δbp mini-gene contain 
the branchpoint sequence.  Primer C was used for RT-PCR, primer pairs C and D were 
used for the initial PCR and primer pairs A and B were used for the final nested PCR.  
(D)  Sequence for the 3’ end of intron 4 (in lowercase) and part of exon 5 (capitalized) is 
shown.  Dots correlate with lariats that were sequenced to the particular nucleotide it is 
placed above or under and are color coded to the branchpoint adenosine that was likely 
used.  The 5 nucleotides that were deleted in the Δbp mini-gene was the most commonly 
used branchpoint.  Other branchpoint sites that weren’t used as often were located at the 
3’ end of the PY tract, between the PY tract and the 3’ ss and the first nucleotide of exon 
5.  
MBNL1 binds a primarily unstructured region between the distant branchpoint 
and 3’ splice site- To determine the structure of the highly conserved intronic region of 
intron 4 and to identify the binding sites for MBNL1, we performed RNA structure 
probing and footprinting experiments.  This was done with a 491 nucleotide RNA that 
contains the last 207 nucleotides of intron 4, all 54 nucleotides of exon 5 and the first 227 
nucleotides of intron 5.  This RNA included the 212 nucleotide ultra-conserved element, 
which spans the intronic region upstream and downstream of exon 5, as well as exon 5 
itself.  Additional sequence upstream and downstream of the ultra-conserved element was 
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used to favor the native secondary structure.  Because a larger stretch of sequence 
upstream of exon 5 is highly conserved and contains proposed MBNL1 binding sites, we 
focused our structure probing and footprinting studies on this region of the RNA.  
Both SHAPE (Selective 2’ Hydroxyl Acylation by Primer Extension [50]) and 
RNases were used to determine the secondary structure of the 3’ end of intron 4.  RNase 
T1 cleaves after single-stranded guanosine residues, RNase 1 cleaves after single 
stranded nucleotides with a bias for single-stranded pyrimidines and SHAPE uses NMIA 
(N-methylisatoic Anhydride) to form 2’-O-adducts.  NMIA reacts with all nucleotides 
and the extent of the modification is dependent on the flexibility of the nucleotide [50].  
Shown in Figure 13A–C are representative gels of all three assays.  The quantified (see 
Materials and Methods) readout from these experiments was fed into RNAStructure 
(Reuter et al., 2010) to create the secondary structure shown in Figure 13F (only 
nucleotides 42–210 were quantified).  The RNA appears to have a structured 5’ end, a 
primarily unstructured linker region that contains several of the proposed MBNL1 
binding sites and then a more structured region that contains the end of intron 4.  
Secondary structure of exon 5 and intron 5 are predictions from the RNAStructure 
program.  The distant branchpoint sequence is at the junction of two helices with a large 
bulge that contains the PY tract.  The 3’ ss is also at the junction of RNA structural 
elements.   
To determine where MBNL1 binds within this RNA, footprinting with T1 and R1 
RNases were performed.  These experiments revealed that the addition of 5µM MBNL1 
changed the cleavage pattern at a number of nucleotides.  The differences in cleavage 
(see lane 3 in Figure 13A–B) were quantified by subtracting the averages of the reactivity 
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profiles in the presence and absence of MBNL1 and normalizing the data as described in 
the experimental procedures section (Figure 13D–E).  Only nucleotides that showed a 
difference of more than 0.2 for RNase T1 and RNase 1 are shown in figure 13F (red 
represents reduced cleavage and blue represents enhanced cleavage in the presence of 
MBNL1).  For example, G144 showed a large reduction in cleavage by RNase T1 
suggesting MBNL1 interacts with this nucleotide.  G137, which is located within a 
YGCY motif, and G156 (in UGCG motif) also show significant protection by MBNL1 
(Figure 13D and 13F).  It is interesting that out of the ten YGCY motifs within the last 
141 nucleotides of intron 4, only two YGCY motifs show a footprint (nucleotides G137 
and G141).   However, nucleotides near YGCY motifs, such as G144–G150, G156, C175 
and A196 also show an increased amount of protection suggesting MBNL1 interacts with 
these nucleotides. Although it appears that there are differences in the RNase T1 cleavage 
upstream of G86 (Figure 13A, lanes 2 and 3), quantification of 3 different gels showed no 
significant difference.  Interestingly, some nucleotides are cleaved more in the presence 
of MBNL1, such as nucleotides G150, C167, C172, G173, G176, G198, C190, G194, 
G197 and G201.  Nucleotides with enhanced cleavage near protected sites could be due 
to MBNL1 affecting the local secondary structure of the RNA. 
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Figure 13. Structure probing and footprinting of the 3’ end of intron 4 of MBNL1 pre-
mRNA. (A) T1 RNase (cleaves single stranded guanosines) was used for structure 
probing and footprinting purposes.  Lane 1 is the free RNA, lane 2 has RNA and T1 
RNase and lane 3 includes RNA, MBNL1 and T1 RNase.  Lane 3 shows a footprint 
between nucleotides G126 and G162. (B) RNase 1 (cleaves single stranded pyrimidines) 
was used for structure probing and footprinting purposes.  Lanes are similar to that 
described in Figure A except RNase 1 is being used.  Lane 3 shows footprinting between 
nucleotides G126 and G162. (C) SHAPE (used to indicate flexible nucleotides) was used 
to determine the secondary structure of the intronic region upstream of exon 5.  (D) A 
difference plot of the T1 RNase data was created by subtracting the footprinting data 
(lane 2) from the structure probing data (lane 1) of the T1 RNase gels.  (E) A difference 
plot of the R1 RNase data was created in the same way as for Figure D.  The difference 
plots in panels D and E focus on the region between nucleotides G126 and G210.  (F) 
Secondary structure of part of intron 4, exon 5 and part of intron 5.  Intron 4 contains data 
from T1, RNase 1 and SHAPE gels.  Nucleotides that are highlighted in yellow are in 
exon 5.  Exon 5 and intron 5 structure predictions are based solely on predictions from 
the RNAStructure program and include no experimental data. Nucleotides in red are 
nucleotides that are footprinted to in the T1 RNase and R1 RNase assays.  Nucleotides in 
blue are nucleotides that saw greater cleavage in the presence of MBNL1.  The adenosine 
in green is the distant branchpoint and nucleotides in brown are the PY tract.  Outlined 
nucleotides are potential MBNL1 binding site (YGCY motifs).   
 
Identification of a 90 nucleotide MBNL1 regulatory element in the 3’ end of 
intron 4- To determine if the region of intron 4 protected by MBNL1 is required for 
MBNL1 to negatively regulate exon 5, this section of RNA was deleted from the MBNL1 
mini-gene and replaced by an Mfe1 cut site.  Ninety nucleotides between the distant 
branchpoint and 3’ ss were deleted, resulting in an intron 4 lacking all YGCY motifs 
except two located upstream of the branchpoint.  This deletion (Δ90) also resulted in an 
intron that was more similar to canonical introns in which the PY tract and branchpoint 
are found closer to the 3’ ss (Figure 14A).  Splicing of the Δ90 mini-gene results in 
almost complete inclusion of exon 5 (Figure 14B) and the over-expression of MBNL1 
did not alter the splicing pattern (Figure 14B), indicating that this region of the intron 
(MBNL1 response element) is required for regulation by MBNL1.  Interestingly, this 
element doesn’t appear to contain any essential positive splicing signals for exon 5.    
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 To characterize the binding of MBNL1 to this response element, a gel shift assay 
was performed with this RNA.  MBNL1 binds this RNA with high affinity (at 30nM 
protein, nearly all RNA is bound, lane 6 in Figure 14C).  It appears that several MBNL1 
proteins bind this RNA because three different complexes can be distinguished (Figure 
14C).  This result is not surprising given that this 90 nucleotide RNA contains 10 YGCY 
motifs.  
 In an effort to determine if the MBNL1 response element could be pared down to 
a more minimal element, smaller deletions in this region were made.  Del 1 Δ18 
eliminated the two YGCY motifs closest to the PY tract, Del 2 Δ16 eliminated the next 
two downstream YGCY motifs, Del 3 Δ18 eliminated one YGCY motif, Del 4 Δ19 
eliminated one YGCY motif and Del 5 Δ18 eliminated a string of four YGCY motifs 
(Figure 14A).  Del 1 Δ18, Del 3 Δ18 and Del 5 Δ18 all resulted in an increase of exon 5 
inclusion (Figure 14D) where levels ranged from 82% to 99% where as Del 2 Δ16 and 
Del 4 Δ18 both resulted in wild type levels of exon 5 inclusion.  In all deletions MBNL1 
was still able to inhibit exon 5 inclusion and the effect of MBNL1 over-expression is 
strong in all cases (levels range from 7% to 14% inclusion of exon 5).  These results 
indicate that the loss of one to four YGCY motifs in the MBNL1 response element is not 
sufficient to abrogate MBNL1’s ability to regulate exon 5 splicing.   
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Figure 14. 90 nucleotides between the PY tract and 3’ splice site are required for MBNL1 
auto-regulation.  (A) A schematic representation of the non-canonical intron 4 of MBNL1 
and sequence of the 90 nucleotide (sequence shown) MBNL1 response element. Black 
hatch marks indicate instances of YGCY motifs and the thickness of the hatch mark 
indicates the frequency of YGCY motifs.  These 90 nucleotides (sequence shown) were 
removed from the mini-gene to create the Δ90 construct.  Shorter deletions within the 90 
nucleotide region are indicated below the sequence and YGCY motifs are highlighted.  
(B) Splicing of Δ90 mini-gene in HeLa cells in the absence and presence of 
overexpressed MBNL1.  (C) Gel shift of the 90 nucleotides deleted in the Δ90 minigene.  
Concentrations of the protein increase from left to right: 0 nM, 0.026 nM, 0.2 nM, 0.9 
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nM, 6 nM, 30 nM, 200 nM and 1200 nM.  (D) Splicing results of the smaller deletions 
within the 90 nucleotide sequence shown in panel A.  
 
Materials and Methods 
 
Labeling of RNAs for gel mobility shift assay- The RNA was transcribed from 
purified PCR product using T7 RNA polymerase and [α-P32] CTP.  The RNA sequence 
including the T7 site is 5’– GAUAAUACGACUCACUAUAGGGUGCUGCCCCCAUG 
AUGCCCUCUGCUUGCUGUUUAUGUUAAUGCGCUUGAACCCCACUGGCCCAU
UGCCAUCAUGUGCUCGCUGCCUGCU –3’.  The T7 site as well as the three 
additional guanosines added are underlined. 
Gel mobility shift assay- Gel mobility shift assay was performed as previously 
described [40] except for the following changes. Reactions were run on a 5% 
polyacrylamide gel (.5X TBE, 5% 37.5:1 acrylamide:bisacrylamide and 4% glycerol).  
The gels were run for 2 hours at 4ºC at 170V. 
Construction of splicing reporter constructs- The MBNL-eGFP construct was 
obtained from the laboratory of Maury Swanson [51] and the DMPK-CUG960 plasmid 
was obtained from the laboratory of Thomas Cooper [38].  The wild type MBNL1 
minigene was made by amplifying regions of the MBNL1 gene containing 51 nucleotides 
from the 3’ end of intron 3, exon 4, intron 4, exon 5, intron 5, exon 6 and 33 nucleotides 
of the 5’ end of intron 6 from HeLa genomic DNA using PCR primers with unique 
restriction sites.  The forward primer (5’–CCACAGGATCCGCTTC 
TTCTTCTTCATGTTGACTAAACCTCATG–3’) contained a BamHI site and the 
reverse primer (5’–ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCA 
CCCC–3’) contained a NotI site.  The amplified genomic DNA was cut with BamHI and 
NotI and inserted into a pcDNA3 plasmid and sequenced. 
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The Δbp minigene was made by deleting 5 nucleotides using standard PCR 
techniques.  The Δbp minigene was created in two segments.  The first segment was 
created by using the forward primer 5’– CCACAGGATCCGCTTCTTCTTCTTCATGT 
TGACTAAACCT CATG–3’ and the reverse primer 5’–GGGTAGGTGAGAAAAAAC 
AAATAAAAAAACAACGGAATGCCATATACAACGAATAACAAG–3’.  The 
second segment was made using the forward primer 5’–TTGTTTTTTTATTTGTTTTTT 
CTCACCTACCCAAAAATGCACTGCTGCCCCC–3’ and the reverse primer 5’–
ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCACCCC–3’.  Both 
segments were then used in the same PCR reaction and the forward primer 5’–
CCACAGGATCCGCTTCTTCTTCTTC ATGTTGACTAAACCTCATG–3’ and reverse 
primer 5’–ATTCTTATGCGGCCGC CAGATTCATTTATTAAGAAACCCCACCCC–
3’ were used to PCR amplify the minigene.  The PCR product was cut with BamHI and 
NotI and ligated into a pcDNA3 plasmid and sequenced. 
The Δ90 minigene was made in two segments.  The first segment was made using 
the forward primer 5’– CCACAGGATCCGCTTCTTCTTCTTCATGTTGACTAAACCT 
CATG–3’ and reverse primer 5’– GGCTTTCAATTGGTGCATTTTTGGGTAGGTGAG 
AAAAAACA–3’.  The second segment was made using the forward primer 5’–GGCTTT 
CAATTGAATTAAGACTCAGTCGGCTGTCAAATCAC–3’ and the reverse primer 5’–
ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCACCCC–3’.  Segment 
1 was cut with Mfe1 and BamHI and segment 2 was cut with Mfe1 and NotI.  Segment 1 
and 2 were then ligated into a pcDNA3 plasmid and sequenced.  
The Del 1 Δ18 minigene was made in two segments.  The first part of the segment 
was made by using the forward primer 5’–CCACAGGATCCGCTTCTTCTTCTTCATG 
 42
TTGACTAAACCTCATG–3’ and the reverse primer 5’–CATTAACATAAACAGCAA 
GCAGAGGGTGCATTTTTGGGTAGG–3’.  The second segment was made using the 
forward primer 5’–CCTCTGCTTGCTGTTTATGTTAATGCGCTTGAACC–3’ and the 
reverse primer 5’–ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCAC 
CCC–3’.  The two segments were ligated using standard PCR techniques and was 
inserted into a pcDNA3 plasmid and sequenced.   
The Del 2 Δ16, Del 3 Δ18, Del 4 Δ19 and Del 5 Δ18 minigenes were made using 
the PCR techniques described for the Del 1 Δ18 minigene.  All Del minigenes used the 
same forward primer for the first segment and the same reverse primer for the second 
segment.  The Del 2 Δ16 minigene used the reverse primer 5’–GGTTCAAGCGCATTA 
ACATGCATCATGGGGGCAGC–3’ for the first segment and the forward primer 5’–TG 
TTAATGCGCTTGAACCCCACTGGCCCATTGC–3’ for the second segment.  The first 
segment of Del 3 Δ18 minigene was made using the reverse primer 5’–CATGATGGCA 
ATGGGCCAGTGGTAAACAGCAAGCAGAGG–3’ the second segment was made 
using the forward primer 5’–CCACTGGCCCATTGCCATCATGTGCTCGC–3’.  The 
first segment of the Del 4 Δ19 minigene was made using the reverse primer 5’–GCAGGC 
AGCGAGCACATGGGTTCAAGCGCATTAAC–3’.  The second segment of the Del 4 
Δ19 minigene was made using the forward primer 5’–CATGTGCTCGCTGCCTGCTAA 
TTAAGACTCAGTCGG C–3’.  The first segment of the Del 5 Δ18 minigene was made 
using the reverse primer 5’–GACAGCCGACTGAGTCTTAATTATGGCAATGGGCCA 
GTGG–3’.  The second segment of the Del 5 Δ18 minigene was made using the forward 
primer 5’–AATTAAGACTCAGTCGGCTGTCAAATCACTGAAGCGACCCC–3’. 
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Cell culture and transfection- HeLa cells were cultured and transfected as 
previously described [40] except for the following changes.  1X Antibiotic-Antimycotic 
(Invitrogen) was added to DMEM GLUTAMAX  media (Invitrogen).  Cells were 
harvested 16-24 hours after transfection. 
In vivo splicing- Splicing assays were done as described in Murray et al., 2008 
except for the following changes.  All reporters were reverse transcribed using a pcDNA3 
plasmid specific antisense primer 5’–AGCATTTAGGTGACACTATAGAATAGGG–3’.  
The –RT reactions were treated the same as the +RT reactions except that no 
SuperScriptII was added to the –RT reactions.  The cDNA from the RT reaction (2µL) 
was subjected to 26 rounds of PCR (within linear range) in a 20µL reaction.  PCR 
amplification for all splice products was done using the sense primer 5’– GATCAAGGC 
TGCCCAATACCAG –3’and the antisense primer 5’–ATTCTTATGCGGCCGCCAGA 
TTCATTTATTAAGAAACCCCACCCC–3’.  The  PCR products were resolved on a 6% 
native polyacrylamide gel (40% 19:1 acrylamide:bisacrylamide) using SYBR Green 
(Applied Biosystems). The SYBR Green was diluted 1000X in 6X dye.  Quantification of 
bands was done using the Alpha Imager HP Software from Alpha Innotech.  Percent exon 
inclusion was calculated by dividing the amount of the band indicating inclusion by the 
total amount of splice product (bands indicating inclusion and exclusion).  Background 
was taken from space between the two bands.  
Branchpoint mapping- Branchpoint mapping was done as described in Gao et al., 
2008 except for the following changes [49].  MBNL1 wt minigene was transfected into 
HeLa cells, isolated and DNased as described above.  Antisense primer C (5’- 
GAATAGCTTGTAGTCAGATATAGTTGCTC -3’) was used to reverse transcribe 
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using Super Script III.  Lariat PCR was done using primers C and sense primer D (5’- 
GCAGACTCTCTCCTCCTCTCTTCC – 3’) and nested PCR was done using antisense 
primer A (5’- GCTTTTCTGACTGCTAACAAGGAGAGAGC -3’) and sense primer B 
(5’- TAATTAACTACAAAGAGGAGTTATCCTCCC -3’). Nested lariat RT PCR 
products were purified using PCR Cleanup (Qiagen) and individual lariats were isolated 
by Topo cloning (Invitrogen) and  sequenced. 
Protein purification- The MBNL1 protein construct, which includes amino acids 
1–260 and contains an N-terminal GST tag, was expressed and purified as described in 
Warf et al., 2007, except for the following differences [39].  For the lysis of bacterial 
cells, 10µg/mL of DNase was added with the lysozyme (1mg/mL) and the cell extract 
was centrifuged for 30 minutes at 15,000 rpm.  Supernatant was loaded onto GST beads 
and washed with PBS-T buffer (1X PBS and 1%Triton X-100) and eluted with elution 
buffer (10mM reduced glutathione, 50mM Tris pH 9.5).   
Transcription of unlabeled RNA- The RNA used for structure probing and 
footprinting was transcribed from DNA amplified from the MBNL1 pcDNA3 construct 
used to transfect HeLa cells using sense 5’–GATAATACGACTCACTATAGGGACAA 
CTCAGTAGTGCCTTTATTGTGCATGCTTAGTCTTGTTATTCGTTGTATATGGCA
TTCCG –3’ (T7 site and additional guanosines are underlined) and the antisense primer 
5–GGGCTGCTGGGCTTTC–3’. To amplify the template, 35 rounds of PCR were done.  
The template was subjected to PCR cleanup using the PCR cleanup Qiagen kit.  To 
transcribe, 100–500ng of DNA was added to each Transcription Reaction: 40mM Tris pH 
8, 10mM MgCl2, 2mM spermidine, 0.01%Triton, 1X rNTP, 10mM DTT, 1 unit of 
RNasin (Promega), 40% PEG and T7 DNA polymerase at 37°C for 1.5 to 2 hours. 1 unit 
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of DNase was added to the transcription and incubated at 37°C for 1 hour.  The RNA 
sample underwent phenol chloroform and was run on an 11% denaturing gel (7.5M urea, 
11% 29:1 acrylamide:bisacrylamide and 1X TBE).  RNA was eluted using an Elutrap and 
the RNA was EtOH precipitated.  The RNA pellet was brought up in low TE and 
quantified using the Qubit (Life Technologies).  RNA was stored at –80°C. 
Footprinting and Structure Probing with T1 and RNase 1- RNA, Structure Buffer, 
and heparin were snap annealed. The mixture was aliquoted and different concentrations 
of GST tagged MBNL1 were incubated with the RNA sample for 15 minutes at room 
temperature.  Then 0.25U of T1 RNase or 0.3U of RNase 1 was added and the sample 
was incubated for an additional 15 minutes (structure probing experiments were done 
without MBNL1).  A final concentration of 81nM RNA, 0.48µg of heparin in T1 RNase 
Structure Buffer (final concentration of 7.7mM Tris pH 7, 77mM KCl, 7.7mM of MgCl2) 
and R1 RNase Structure Buffer (final concentration of 7.7Mm Tris pH 7, 77mM NaCl, 
7.7mM MgCl2) was EtOH precipitated by adding 20µl of inactivation buffer (0.7M 
NaOAC pH 5.2 in EtOH) and 1µL of 20mg/mL of glycogen.  Samples were incubated on 
ice for 5 minutes, and spun at max speed for 15 minutes at 4°C.  Pellets were resuspended 
in a final concentration of 18nM of radiolabeled reverse primer (5’–
CAGGTCAAAGGTTGCCTCG–3’) and 0.83mM dNTPs (the reverse primer was 
kinased using Polynucleotide Kinase and [γ-P32] ATP). Samples were incubated at 65°C 
for 5 minutes, 35°C for 5 minutes and on ice for one minute. Reverse transcription was 
carried out by adding appropriate amounts of 5X First Strand buffer, 0.1M DTT, and 
200U of SuperScript III.  Samples were incubated at 52°C for 1 hour and at 70C for 15 
minutes.  Samples were then phenol chloroformed, EtOH precipitated and the pellet was 
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resuspended in 20µL of low TE.  An equal volume of 2X Denaturing dye was added to 
the samples, which were then incubated at 95°C for 2 minutes and run on an 8% 
denaturing gel (8% 19:1 acrylamide:bisacrylamide, 1X TBE and 7.5M urea) 
The SHAPE (Selective 2’ Hydroxyl Acylation by Primer Extension) assay was 
done as described above, except RNA and heparin were snap annealed in HE buffer  
(10mM HEPES pH 8.0 and 1mM EDTA pH  8.0).  1X Folding mix buffer (Recipe for 3X 
buffer is 333mM HEPES pH 8.0, 20mM MgCl2, 333mM NaCl) was added and the RNA 
sample was incubated at 37°C for 20 minutes.  RNA samples were aliquoted and 1µL 
NMIA in neat DMSO were added to samples.  Neat DMSO was added to a sample as a 
control (free RNA).  Reactions were incubated at 37°C for 45 minutes.  Inactivation 
buffer was added and reverse transcription was done as described above. 
Quantification and normalization of T1, RNase 1 and SHAPE gels- Footprinting 
and structure probing data was quantified using the SAFA program [52].  Data was 
normalized for each lane as described in Low et al. 2010 [53].  The sequence and text 
files were imported to the RNAStructure programs (available from 
http://rna.urmc.rochester.edu/rnastructure.html) [54].  The slope (m) and intercept (b) 
chosen were 2.6kcal/mol and –0.8kcal/mol, respectively. 
Difference plots were made by subtracting normalized reactivities of the protein 
lane from the no protein lane.  The average of the difference was then added and the 
values were plotted.  The sequence and SHAPE text files were prepared as described in 
Low et al., 2010. 
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Discussion 
PTB1 and MBNL1 negatively regulate splicing of their pre-mRNAs through 
introns containing distant branchpoints- PTB1 (polypyrimidine tract binding protein 1), 
also known as hnRNP I, is an alternative splicing factor that regulates many different 
splicing events [55].  Like MBNL1 and MBNL2, this factor also auto-regulates the 
splicing of its own pre-mRNA through the usage of a predicted distant branchpoint [56].  
The distant branchpoint is contained within a 351 nucleotide AGEZ in intron 10 of the 
PTB1 pre-mRNA [56].  The auto-regulation of PTB1 leads to exon 11 exclusion, 
resulting in a premature termination codon that is predicted to induce the NMD (nonsense 
mediated decay) pathway.  This auto-regulation of splicing allows PTB1 to tightly 
control its own protein levels.  MBNL1 and MBNL2 differ in that their auto-regulation 
leads to different protein isoforms.  Presumably, these different isoforms of MBNL1 and 
MBNL2 have different functions, but currently the major known difference between the 
isoforms is that those lacking exon 5 are found in both the nucleus and cytoplasm while 
the isoforms containing exon 5 are primarily nuclear [46].   
A non-canonical intron in the MBNL1 pre-mRNA- The 3’ end of MBNL1 intron 4 
is different than the 3’ end of most other introns.  First, the 3’ end of intron 4 is contained 
within an ultra-conserved element longer than 200 nucleotides, and is one hundred 
percent conserved between human, rat and mouse genomes [44].  Second, this intron is 
unique because it contains a distant branchpoint and an AAG 3’ splice site.  Most human 
introns contain a predicted branchpoint in the last 40 nucleotides of the intron and a YAG 
3’ ss.  In the canonical intron architecture, U2AF35 binds the 3’ ss, U2AF65 binds the 
PY tract and U2 snRNP binds at the branchpoint [57].  It is not clear how these factors 
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recognize introns containing distant branchpoint sequences.  However, it has been 
suggested that the second step in splicing may involve a mechanism in which the 
spliceosome performs a linear scan downstream from the distant branchpoint and PY 
tract until it reaches the first AG dinucleotide [58, 59].  Antibodies to the polypyrimidine 
tract binding protein were used to analyze components that assemble on alternatively 
spliced pre-mRNAs that use a distant branchpoint [60]. Out of two pre-mRNAs studied 
(α and β-TM), the group identified a common set of uncharacterized proteins, in addition 
to PTB1, that assemble on alternatively spliced pre-mRNAs with distant branchpoint 
sequences. However, it is unclear how these proteins aid in alternative splicing [60].   
One possible mechanism is that the 141 nucleotide RNA linker contains binding 
sites for proteins that interact with U2AF35, U2AF65 and U2 snRNP that facilitate their 
binding and spliceosome formation.  Alternatively, this RNA linker may be sequestered 
out of the way (likely bound by hnRNPs) in some manner (Figure 15A).  It has been 
shown that the presence of a stem-loop between a distant branchpoint and 3’ ss inhibits 
the second step of splicing [61].  It is possible that like the stem-loop, MBNL1 binding to 
this region of the intron results in a structure that blocks scanning to the 3’ ss (Figure 
15B).  The inability to splice this pre-mRNA in vitro has blocked our efforts to determine 
at which step MBNL1 is regulating splicing.   
A recent bioinformatics study suggests that highly conserved regions are actually 
less structured compared to other regions of the pre-mRNA [62] and our structure 
probing data for MBNL1 is consistent with this hypothesis.  It is possible that this lack of 
structure within highly conserved regions make them more accessible to splicing factors 
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for regulation, and if these sites are highly regulated by multiple splicing factors, then 
higher conservation seems plausible.   
MBNL1 regulates MBNL1 exon 5 through a dissimilar mechanism than CLCN1 
exon 7A and TNNT2 exon 5- Studies of where MBNl1 binds its pre-mRNA targets to 
regulate alternative splicing suggests that MBNL1 may not regulate exon exclusion 
through a conserved mechanism.  In intron 4 of the MBNL1 pre-mRNA, we observed that 
MBNL1 regulates exon 5 exclusion by binding a response element located within an 
AGEZ just downstream of a distant branchpoint and PY tract.  In the CLCN1 pre-mRNA, 
MBNL1 represses exon 7A inclusion by binding the 5’ end of exon 7A (which contains 
an ESE) and flanking intronic regions [27].  Previously, we showed that MBNL1 and 
U2AF65 compete for binding at the 3’ end of intron 4 of the TNNT2 pre-mRNA to 
regulate exon 5.  MBNL1 regulated TNNT2 exon 5 exclusion may involve MBNL1 
binding the RNA in a looped conformation based on a model from a crystal structure of 
MBNL1 in complex with a short RNA, while U2AF65 interacts with the RNA in a 
single-stranded conformation [29, 31]. 
The binding of multiple MBNL1 proteins to the MBNL1 intron 4 linker may result 
in the RNA adopting a conformation that inhibits formation of a functional splicing 
complex at this 3’ ss.  Footprinting and structure probing data shows that MBNL1 binds a 
mostly unstructured part of the RNA (nucleotides 137-162) and causes more cleavage of 
nucleotides just downstream (nucleotides 167-201), suggesting that upon binding, 
MBNL1 may cause downstream RNA to become unstructured allowing more MBNL1 
proteins to bind (Figure 12C).  In the presence of MBNL1, the 3’ss of intron 4 is not 
accessible to the spliceosome, resulting in the exclusion of exon 5 (Figure 15B).  The 
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MBNL1 response element doesn’t overlap with the branchpoint, PY tract or 3’ splice site; 
therefore, direct competition between MBNL1 and constitutive splicing factors doesn’t 
appear to be a likely mechanism for regulation by MBNL1.  It is possible that additional 
MBNL1 proteins bind outside of the response element to compete with constitutive 
splicing factors or alternatively the presence of MBNL1 blocks the ability of the splicing 
machinery to locate (via scanning) the 3’ ss from the distant branchpoint. 
 
Figure 15.  Model for MBNL1 binding and excluding exon 5.  (A) Intron 4 of the 
MBNL1 pre-mRNA contains a distant branchpoint, PY tract and a 141 nucleotide AGEZ 
that contains an MBNL1 response element.  When MBNL1 is not present to regulate 
alternative splicing, ISEs (intronic splicing enhancers) and ESEs (exonic splicing 
enhancers), along with other proteins, regulate exon 5 inclusion.  (B) MBNL1 binds the 
90 nucleotide regulatory region in the AGEZ to regulate exon 5 exclusion.  By binding 
within the AGEZ, MBNL1 appears to inhibit the ability of the spliceosome to locate the 
3’ ss.  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions to Chapter II 
 Results from the Mbl SELEX study discussed in Chapter II showed that the 
sequence AGUCU was enriched in the SELEX RNAs.  Characterization of SELEX RNA 
#20 showed that Mbl required both stem-loops to bind and truncation of stem-loop 1 
could be tolerated.  Removal of either the 5’ or 3’ tail of SELEX RNA #20 resulted in 
loss of binding by Mbl.  However, since the AGUCU motif in Class I and Class II RNAs 
bound the constant regions the SELEX may have been biased and the AGUCU and 
additional studies will have to be done to search for a biologically relevant RNA 
sequence that Mbl binds.  However, the binding studies that were done to characterize the 
different SELEX RNAs show that Mbl can bind structured RNAs.  Determining whether 
MBNL1 can bind the SELEX RNAs (that contain one or more AGUCU motifs) and the 
RNA #20 mutants would provide insight as to whether MBNL1 and Mbl recognize RNA 
in a similar manner. 
Conclusions to Chapter III 
Round 5 SELEX sequences were sequenced and a common YGCY motif was 
identified.  The sequences were further organized into two classes, Class I, which had one 
or more YGCY motifs and Class II, which had zero to one YGCY motif.  Interestingly, 
MBNL1 bound Class I RNAs with higher affinity than class II RNAs.   
The YGCY motif was used to determine potential MBNL1 binding sites within 
the pre-mRNAs that are mis-spliced in myotonic dystrophy.  We searched 200 
nucleotides upstream, downstream and even within the regulated exon of the pre-mRNA 
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for YGCY motifs in the 24 pre-mRNA transcripts shown to be mis-spliced in myotonic 
dystrophy.  We choose 5 pre-mRNA transcripts out of the 24 to study in more detail.  40-
45 nucleotide regions of the MBNL1, MBNL2, SERCA1, GRIN1 and INSR pre-mRNAs 
that contained YGCY motifs were studied.  
RNAs that bound MBNL1 with high affinity not only had one or more YGCY 
motifs but also contained a high percentage of pyrimidines.  Closer observation of 
MBNL1 site #1 revealed that the it lied within an ultraconserved element upstream of the 
MBNL1 regulated exon (exon 5).  Mutational analysis of MBNL1 site #1 revealed that 
there are probably many MBNL1 binding sites upstream of exon 5 within the MBNL1 
pre-mRNA.  Although simple mutagenesis abolishes MBNL1’s ability to bind the 45 
nucleotide MBNL1 CA_CAP in vitro, the MBNL1 CA_CAP mutant does not affect 
MBNL1’s ability to regulate exon 5 exclusion in vivo.  This suggests that MBNL1 may 
regulate exon 5 exclusion by binding multiple YGCY motifs within intron 4 outside of 
MBNL1 site#1. 
Further characterization of the endogenous potential MBNL1 binding sites will 
provide insight as to where MBNL1 binds its pre-mRNA targets to regulate alternative 
splicing.  Observations from this type of study may lend more support to the hypothesis 
that MBNL1 and U2AF65 compete for a binding site, or may suggest alternative 
mechanisms by which MBNL1 may regulate its pre-mRNA targets. 
Conclusions to Chapter IV 
 The identification of two potential binding sites upstream of exon 5 in the MBNL1 
pre-mRNA prompted a series of experiments to determine whether MBNL1 regulates the 
alternative splicing of it’s own pre-mRNA through these sites.  We observed that the 3’ 
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end of intron 4 is non-canonical in that it contains an AG exclusion zone and an AAG 3’ 
ss. 
To determine whether the ultraconserved region between the potential PY tract 
and 3’ splice site was important for splicing, a mutant MBNL1 minigene was made where 
90 nucleotides were deleted between these two regions.  This minigene (Δ90) was 
designed so that the potential PY tract would only be 28 nucleotides away from the 3’ 
splice site. The Δ90 minigene was transfected into HeLa cells and exon 5 inclusion was 
seen as it is seen in wild type cells (Figure 12).  When the Δ90 minigene is transfected 
into HeLa cells and MBNL1 is overexpressed, MBNL1 is no longer able to regulate 
exclusion of exon 5.  Interestingly, the deletion contains the area in which there was a 
footprint upstream of exon 5.  Smaller deletions within the 90 nucleotide MBNL1 
response element did not obliterate MBNL1’s ability to regulate exon 5 exclusion.  This 
observation is consistent with the in vivo slicing of the MBNL1 CA-CAP mutant 
discussed in Chapter III, where the mutation of a handful of YGCY motifs does not affect 
MBNL1’s ability to regulate exon 5 exclusion.   
Further characterization by footprinting and structure probing of MBNL1 intron 4 
showed that intron 4 contains a mostly structured distant bp and PY tract and a largely 
unstructured MBNL1 response element. These results confirm that MBNL1 can bind 
unstructured, single stranded RNA.  Footprinting and branchpoint mapping results have 
led to the hypothesis that MBNL1 may not regulate exon 5 exclusion by competing with 
the splicing factor U2AF65 as was suggested for the TNNT2 pre-mRNA (Warf et al., 
2009).  This is because the YGCY motifs (MBNL1 binding sites) do not overlap with the 
distant polypyrimidine tract, however U2AF65 binding to MBNL1 intron 4 has yet to be 
 54
studied. 
It has been shown that MBNL1 requires a 90 nucleotide sequence upstream of 
exon 5 in the MBNL1 pre-mRNA to regulate exon exclusion. It will be interesting to 
determine if this 90 nucleotide sequence is sufficient for MBNL1 regulation.  This could 
be done by placing the 90 nucleotide element into a heterologous pre-mRNA that is not 
regulated by MBNL1.  If MNBL1 regulates this heterologous pre-mRNA this 
demonstrates that this elements contains all of the necessary signals for MBNL1 splicing 
regulation.   
 Once a minimal RNA sequence required for MBNL1 dependent regulation is 
found, this construct can be incubated with HeLa nuclear extract to determine whether 
MBNL1 inhibits a particular complex (E, A, B or C) formation by binding the intron 4. 
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